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Abstract
Background: Immunological protection via breastfeeding is well known. The immunological profile of human milk
changes during lactation. No clinical trials have been conducted in lactating women with the newest mRNA
vaccines against SARS- CoV-2. A Few studies have shown the presence of antibodies in breastmilk after vaccination.
The aim of this work is to study possible antibodies transfer via breastmilk and also the immunological
characteristics of lactating women compared to non-lactating women, after using the BNT162b2 Pfizer vaccine.
Methods: This is a prospective cohort study with a convenience homogenous sample of 24 healthcare workers (14
lactating and 10 non-lactating women) enrolled at the time of COVID-19 vaccination. Clinical data was registered in
a questionnaire. Titers of SARS-CoV-2 spike IgG, IgA and IgM were quantified in post vaccination blood and human
milk. Antibody quantification was performed by an in-house ELISA to SARS-CoV-2 trimeric spike protein.
Results: All women showed immunity after vaccination with positive antibodies for IgM, IgA and IgG antibodies.
The dominant serum antibody response was IgG. Modest levels of antibodies in breastmilk of lactating mothers
were observed in this study, especially IgG in 42.9%. There was a moderate association between higher titers of IgG
and a longer duration of breastfeeding (R= 0.55, p=0.041).
Conclusions: Evidence of antibody transfer in human milk after COVID-19 vaccination is scarce. The presence of
antibodies in human milk is reported, but immunization through breastfeeding is still to be established.
Keywords: Breastfeeding, Covid-19, mRNA vaccination, Antibodies
Background
In the first months of life, neonates are at greater risk of in-
fections, due to their immature immune system and breast-
feeding will boost immunological responses [1].
Additionally, breastfeeding is proven to be effective against
acute and prolonged infections, and has an influence on in-
fant immune response after mother’s vaccine immunization
[2]. Secretory IgA (SIgA) represents 90% of the antibodies
in human milk, followed by IgM and IgG antibodies [1].
For this reason, and for its biological properties, SIgA is
very important, as it is essential in defending mucous mem-
branes [1]. Nevertheless, specific characteristics of lactating
mothers may influence the kinetics of human milk anti-
bodies due to the differences of previous infections (time
since preexisting disease immunity), age, genetic factors,
and individual immune response [3].
The arrival of COVID-19 vaccines, specifically mRNA
vaccines against SARS-CoV-2 such as BNT162b2 Pfizer,
has raised the question whether they are safe for use in
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the pregnant population and lactating women, because
no clinical trials were conducted on these groups. In the
general population, mainly participants without previous
SARS-CoV-2 infection, there was a 90% efficacy at pre-
venting severe symptoms after two doses were adminis-
tered [4]. The academy of Breastfeeding Medicine does
not recommend cessation of breastfeeding for individ-
uals who are vaccinated against COVID-19 [5]. The
American college of obstetricians and gynecologists rec-
ommend that COVID-19 vaccines should be offered to
lactating individuals as to non-lactating individuals [6].
The potential risks and benefits for these breastfed ba-
bies are still to be determined. Taking into account that
vaccination during pregnancy against other viruses, such
as influenza, was related to specific active antibody pro-
duction throughout lactation, the same may happen in
mRNA vaccines [7].
Gray et al, confirmed that the COVID-19 mRNA vac-
cines result in comparable humoral immune responses
in lactating women to those observed in non-pregnant
populations after studying 31 lactating women in a pro-
spective cohort study. Antibodies and especially SARS-
CoV-2-specific IgG were found in breastmilk [8].
The objectives of this study were to evaluate the sero-
logical profile of lactating women compared to non-
lactating women, after immunization with the
BNT162b2 Pfizer vaccine, in a cohort of healthcare
workers, and study antibody transfer via breastmilk.
Materials and methods
This was a prospective cohort study undertaken between
27 December 2020 and 19 February 2021, with a con-
venience homogeneous sample of 24 healthcare workers
(14 lactating and 10 non-lactating women) enrolled at
the time of COVID-19 vaccination with BNT162b2 Pfi-
zer/BioNTech after advertising the study.
Eligible participants were: 1) lactating and non-
lactating women who underwent vaccination with
BNT162b2 Pfizer; 2) older than 18 years old and able to
provide informed consent.
Demographic data, date and type of delivery, breast-
feeding details, timing of COVID-19 vaccine doses, post-
vaccination symptoms were assessed using a written
questionnaire.
This study was reviewed and approved by the local
ethics committee (NOVA Medical School) as per princi-
ples embodied in the Declaration of Helsinki. Written
informed consent was given by all participants.
Samples collection
A blood sample was collected by venipuncture from all
participants one to three weeks after the first and second
dose of vaccine administration (accordingly with partici-
pants availability). Breastmilk from lactating women was
collected on the same days of blood collection (after the
first and second dose) and collected with breast pump
into sterile containers, being the volume around 100-200
ml (Table 1).SD Standard Deviation
Antibody quantification: Plasma and skim milk isolation
Blood was diluted in PBS 1x (VWR), layered on top of
biocoll (biowest) and centrifuged at 1200xg for 30 min
without a break. Plasma was collected to cryotubes and
stored at -80°C ultra-low freezer until subsequent
analysis.
Skim milk was stored in -20°C freezer until further
analysis. Both biospecimens were immediately processed
and centrifuged at 3000xg for 30 min at room
temperature. ELISA assay was performed based on the
protocol [9] and modified as described in Gonçalves J
et al [10].
Briefly, 96 well plates (Nunc) were coated with 50 μl
of trimeric spike protein at 0.5 μg/mL and incubated
overnight at 4°C. On the following day, the plate was
washed three times with 0.1% PBS/Tween20 (PBST)
using an automatic plate washer (ThermoScientific).
Plates were blocked with 3% of bovine serum albumin
(BSA) diluted in 0.05% PBS/T and incubated for 1 hour
at room temperature. Samples were diluted using 3-fold
dilutions series, starting at 1:50 and ending at 1:10,9350
in 1% BSA-PBST/T and incubated for 1 hour at room
temperature. As previously, Plates were washed three
times and goat anti-human IgA/IgG/IgM-HRP second-
ary antibodies (abcam, ab97225/ab97215/ab97205) were
added at 1:25,000 and incubated for 30 minutes at room
temperature. Plates were washed three times and incu-
bated for around 7min with 50 μl of TMB substrate
(BioLegend). The reaction was stopped with 25 μl of 1M
phosphoric acid (Sigma) and read at 450nm on a plate
reader (BioTek).
Each plate contained 6 calibrators samples from two
high-, two medium-, and two low- antibody producer
from adult individuals collected at Fernando Fonseca
Hospital that were confirmed positive for SARS-CoV-2
by RT-PCR from nasopharyngeal and/or oropharyngeal
swabs in a laboratory certified by the Portuguese Na-
tional Health Authorities [10]. For negative control we
used pre-pandemic plasma samples obtained from
healthy donors collected prior to July 2019.
The endpoint titer was defined as the last dilution
before the absorbance dropped below OD450 of 0.15.
For samples that exceeded an OD450 of 0.15 at the
last dilution (1:10,9350) the end-point titer was deter-
mined by interpolation [9]. Positive immune response
(IgG, IgA and IgM) was considered when ≥ 150 UI/
mL. We calculated IgG and IgA endpoint titers of
SARS-CoV-2 positive individuals by serial 3-fold dilu-
tion and classified end-point titers of 1:150 as low, 1:
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450 as moderate, and ≥1:1.350 as high antibody pro-
ducers, as previously done [9].
Statistical analyses
Continuous variables were expressed as means, standard
deviation and range, whilst categorical variables were
shown as absolute frequencies and percentages. The
study used IBM SPSS® version 23 and RStudio software
[11] for statistical analysis. Correlation analyses were
performed using the Spearman coefficient. Experimental
and control groups antibody levels were compared using
the Wilcoxon-Mann-Whitney non-parametric test. Stat-
istical significance was defined as p <0.05.
Results
Participant’s characteristics are presented in Table 2.
There were no differences between lactating and non-
lactating women in terms of age, smoking habits or co-
morbidities. None of the participants reported a prior
SARS-CoV-2 infection. There was no difference in post
vaccination side effects when comparing lactating versus
non lactating women (p-value = 0.618). The most com-
monly reported side effect was myalgia.
Delivery occurred at term in 92.8% (n=13) of the lac-
tating women and 64.3% (n=9) had a vaginal delivery.
Most lactating women had breastfed over a time period
of 12-24 months at the time of the sample collection.
Exclusive breastfeeding was registered in 2 cases. The
weight of all infants at the time of the study was ≥ 50th
percentile.
All women have shown immunity after vaccination
with positive serum antibodies after the second dose
(Fig. 1). The dominant serum antibody response was
IgG, showing high levels in both lactating and non-
lactating women. (Table 3) However, after the 1st dose
there were higher levels of serum IgG antibodies in the
non-lactating group (W = 112.5, p-value = 0.00531).
Regarding lactating women, serum IgM and IgG iso-
types increased after the 2nd dose. IgA levels reduced
slightly after the 2nd dose, though there was great vari-
ation in individual values (Fig. 2).
The presence of antibodies in breastmilk was detected
after vaccine administration. IgG was present in 7.1% (1/
14) after the 1st dose and increased after the 2nd dose to
42.9 % (6/14). IgA response was present in 35.7% (5/14)
of milk samples after the 1st dose, but showed a reduc-
tion to 21.4% (3/14) after the 2nd dose. No IgM response
was observed following the prime or boost. (Table 2)
When comparing IgA (1st dose) and IgG (2nd dose)
levels between matched serum/milk, there was a ten-
dency for an upward curve and a statistically significant
association between IgG (2nd dose) serum/milk when
adjusting for maternal age and days after dose adminis-
tration (Fig. 3).
We analyzed the relationship of breastfeeding duration
and IgG/IgA response in the milk. Moderate positive
correlation between the two variables (duration of
breastfeeding and milk IgG after 2nd dose) was found
(R= 0.55, p=0.041). Thus, higher titers of IgG are associ-
ated with longer breastfeeding time (Fig. 4a) However,
when adjusted for maternal age and time since the 2nd
dose, this correlation was no longer statistically signifi-
cant. Additionally, the distribution of values for a) does
not appear to be linear.
This is likely owing to the small number of obser-
vations which happened to have the same IgG titer
Table 1 Elapsed time (days) after the 1st and 2nd dose
ID Lactating 1st dose 2nd dose ID Non-Lactating 1st dose 2nd dose
1 10 10 15 22 10
2 8 8 16 22 16
3 8 10 17 22 10
4 10 10 18 22 10
5 13 13 19 22 10
6 9 7 20 22 10
7 8 9 21 22 10
8 8 9 22 23 11
9 7 10 23 23 11
10 12 12 24 23 11
11 10 11 - - -
12 13 10 - - -
13 8 7 - - -
14 16 9 - - -
Mean (SD) 9.5 (2.6) 10 (1.7) Mean (SD) 22.0 (0.5) 10.0 (1.9)
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values. There was a non-significant negative associ-
ation between IgA (2nd dose) and duration of breast-
feeding (Fig. 4b).
All women kept breastfeeding post vaccination. Only
one infant showed different behaviour after maternal
vaccination (somnolence). There was a case of tandem
breastfeeding (brothers) not related to increase transfer
of antibodies to the milk.
Discussion
Pregnant and lactating women were excluded from ini-
tial clinical trials for anti-SARS-CoV-2 vaccination, and
many concerns, especially safety issues, arose related to
vaccination in this specific population. To our know-
ledge, only a few studies have addressed this topic [12–
15]. To date, there are no robust studies regarding the
safety and efficiency of vaccination in lactating women.
Table 2 Participant’s data
Characteristics Lactating women (n= 14) Non-lactating women (n= 10)
Maternal data
Age Median ±SD 33.7 ± 4.95 years 34.5 ±10.6 years
(minimum, maximum) years 26-44 26-62
Caucasian n (%) 14 (100%) 10 (100%)
Smoking habits n (%) 1 (7.1%) 1 (10%)
Comorbidities n (%)
No Comorbidities 8 (57.1%) 6 (60 %)
Hypertension 1 (7.1%) 1 (10%)
Asthma 2 (14.3%) -
Dyslipidaemia 1 (7.1%) 1 (10%)
Thyroid disorders 1 (7.1%) 1 (10%)
Beta thalassemia 1 (7.1%) -
Hodgkin lymphoma - 1 (10%)
Side effects post vaccination n (%)
Myalgia 8 (57%) 6 (60%)
Headache 6 (42.9) 5 (50%)
Local pain 5 (35.7%) 4 (40%)
Nausea 2 (14.3%) 2 (20%)
Fever 1 (7.1%) 2 (20%)
Photophobia 1 (7.1%) 2 (20%)
Tiredness - 3 (30%)
Arthralgia 1 (7.1%) 2 (20%)
Arm numbness 1 (7.1%) -
Delivery data NA
GA at delivery Median ±SD (Range) 38.5 ± 1.7 weeks (range 34-41)
Mode of Delivery n (%)
Caesarean 5 (35.7%)
Vaginal 9 (64.3%)
Infant and Breastfeeding data NA
Birthweight (g) Median ±SD 3263 ± 383 (2460-3800)
Percentile at the time of vaccination 65.5±17 (range 50-97)
Breastfeeding duration n (%)
≤ 2 - 12 months 6 (42.85%)
≥ 12 - 24 months 8 (57.14%)
Exclusive breastfeeding 2 (14.28%)
GA Gestational age, NA Not applicable
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Fig. 1 Distribution of titers over elapsed time (days) after the first dose a and second dose b of the BNT162b2 Pfizer vaccine for lactating (n=14)
and non-lactating (n=10) women. c Percentage of women with vaccine-induced antibodies (antibody titers ≥150) c)
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In the study of Golan et al, mRNA from anti-COVID
vaccines was not detected in human breast milk, this
strengthens the recommendation of maintaining breast-
feeding after inoculation [16]. In a recent study of Fried-
man et al, there is evidence of a rapid production of
vaccine-specific antibodies, both IgA and IgG and neu-
tralizing capacity was proven [17]. Moreover, informa-
tion is needed regarding antibody transfer to breastmilk
and the ability of the infant to receive immunity via
breastfeeding, response that is well established in other
vaccines during pregnancy such as Influenza and Pertus-
sis [18]. Due to the lack of information, our study aims
to add scientific information, allowing future studies to
develop.
In our cohort, the presence of serum antibodies after
vaccine administration was documented in all women.
In a non-infected population, vaccination with mRNA
vaccines elicited spike antigen-specific IgA with similar
kinetics of induction as IgG, although the levels of spike
antigen-specific IgA decreased significantly over time
[13]. We also documented a significant increase in IgG
response after the second dose. On the other hand, IgA
response decreased after the second dose. These results
are comparable to previous studies [12, 13].
Table 3 Antibody titers among lactating and non-lactating women
Antibodies titers Lactating women (n=14) Non-lactating women (n=10)
Blood (Mean) 1st dose (UI/mL) 2nd dose (UI/mL) 1st dose (UI/mL) 2nd dose (UI/mL)
IgG 24250 79264 2700 121500
IgA 880 (4 ND) 600 (2 ND) 260 690
IgM 366 621 530 930
Milk (titer range 150-1350)
IgG 1 (7.1% ) 6 (42.9 %) NA NA
IgA 5 (35.7% ) 3 (21.4%) NA NA
IgM ND ND NA NA













































































































































Fig. 2 Mean blood serology levels in lactating (n=14) and non-lactating (n=10) women after the first and second dose of BNT162b2 Pfizer
vaccine a) Mean IgG, IgA, IgM isotypes (log2) over elapsed time from 1st dose b) Full sample n=24
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An increase in antibody titers in non-lactating women
comparing to lactating women in our study could be ex-
plained by longer time till measurement of titers in non-
lactating group, allowing antibodies to reach their full
peak.Regarding human milk, there was an IgA dominant
response in women that were infected with SARS-CoV-2
[19]. A modest response of antibodies in human milk
with an IgG dominant response was demonstrated. IgA
titers, although present, decreased by the time of the
second dose and no IgM was detected. When comparing
titers of antibodies in serum and milk at the same time
point, a similar response between them was noticed, al-
though, lower levels of antibodies were present in the
milk.
The dominant IgG response in blood and milk after
COVID-19 vaccination can be related to an exposition
of viral spike protein through an intramuscular injection.
Contrarily, greater IgA response is registered in natural
Fig. 3 The Spearman coefficient of correlation (log_2 antibodies) between IgA (1st dose) in milk and serum a, and IgG (2nd dose) in milk and
serum b, adjusted for maternal age and time after the vaccine dose (days)
Fig. 4 a Correlation between breastfeeding duration and milk IgG after 2nd dose. b Correlation between breastfeeding duration and milk IgA
after 2nd dose
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infection, probably due to the fact that infection occurs
in mucosal tissues where IgA response plays an import-
ant role. The mean value of IgG titers after the first dose
(Fig. 2) for non-lactating women is higher than the lac-
tating group due to the inclusion of an outlier value.
This individual was maintained so not to reduce the
sample size further. The fact that after the 2nd dose,
other individuals reached the same magnitude of titers
indicates that the value is not itself senseless, but the
sample size is small to encompass such variations. The
comparison of the values distribution in both groups
after the first dose showed that, in fact, non-lactating
women had significantly higher levels of IgG antibodies.
During lactation, the immunological profile of human
milk changes over time. SIgA is very high in colostrum,
decreasing and remaining stable until 1 year of lactation.
After this period, SIgA and IgG show an upward trend
and IgM remains stable, supporting the importance of
breastfeeding after one year of age for its immunological
protection. These results might be associated with the
higher production of antibodies in lactation over 12
months already demonstrated in other studies [20]. A
correlation was also found between higher titter of anti-
bodies in human milk in women that were breastfeeding
for a longer time, although not significant after adjusting
for maternal age and days after vaccine administration.
Further research is needed for a better knowledge of
longevity of these antibodies in breastmilk and if they
are transferred efficiently to the infant.
Strengths and limitations
One of the strengths of this study is related to the nov-
elty of the topic, since little is known about COVID-19
vaccine immunization and breastfeeding. As breastfeed-
ing brings so many advantages to the newborn and in-
fant, it was considered of extreme importance, studies
regarding vaccine and immune response in this popula-
tion. This is the first study to compare the duration of
breastfeeding with higher levels of antibodies in mater-
nal milk.
In terms of limitations, previous infection to SARS-
CoV-2 could not be ruled out, as no antibody testing
was performed before vaccination. However, participant
self-reported that they were not previously infected and
as they are health workers they are routinely tested. The
small sample size limited statistical inference.
The increased levels of antibodies in non-lactating
women after first dose was higher than in the lactating
group probably due to a longer time until sample
collection.
More than 90% of the human population is seroposi-
tive for at least three Human Coronavirus; therefore
cross reactivity can also be an issue as it is speculated
that this reflects T cell memory to circulating ‘common
cold’ coronaviruses [21].
Conclusion
Currently, the evidence of antibodies transfer in human
milk after COVID-19 vaccination is scarce. This is a first
insight into vaccination and lactation, highlighting the
questions that need to be answered. Also, the belief is, as
per the findings, that long-term lactating women may
show different serological milk responses after vaccin-
ation. Clinical trials are immediately required in this spe-
cific population in order to address scientific based
recommendations.
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